Imaging of Alzheimer's disease

Journal of Neuroimaging

Volumn 13, Issue 3, 2003, Pages 199-214

  Lee, Benjamin C P ^a,b   Mintun, Mark ^a   Buckner, Randy L ^a   Morris, John C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Diagnosis; MR spectroscopy

Indexed keywords

AMYLOID; CHOLINE; CREATINE; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INOSITOL; IODINE 123; N ACETYLASPARTIC ACID; XENON 133;

AGING; ALZHEIMER DISEASE; ANISOTROPY; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN SIZE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ENTORHINAL CORTEX; EVALUATION; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LEUKOARAIOSIS; METABOLITE; NERVE CELL DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; VOLUMETRY; WHITE MATTER;

ALZHEIMER DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0037783995     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403013003001     Document Type: Review

References (136)

1. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Neurology 2001;56:1143-1153.
2. Chiu H, Zhang Q. Evaluation of dementia: a systemic study of the usefulness of the American Academy of Neurology's Practice Parameters. Neurology 1977;49(4):925935.
3. Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001;57(10):17561763.
4. Bahn MM, Parchi P. Abnormal diffusion-weighted magnetic resonance images in Creutzfeldt-Jakob disease. Arch Neurol 1999;56(5):577-583.
5. Hachinski V, Potter P, Mersky H. Leuko-araiosis. Arch Neurol 1987;44:21-23.
6. Scheltens P, Kittner B. Preliminary results from an MRI/CT-based database for vascular dementia and Alzheimer's disease. Ann N Y Acad Sci 2000;903:542-546.
7. Englund E. Neuropathology of white matter changes in Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 1998;9(suppl 1):6-12.
8. Erkinjuntti T, Ketonen L, Sulkava R, Sipponen J, Vuorialho M, Iivanainen M. Do white matter changes on MRI and CT differentiate vascular dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 1987;50(1):3742.
9. Damasio H, et al. Quantitative computed tomographic analysis in the diagnosis of dementia. Arch Neurol 1983;40:715-719.
10. DeCarli C, Kaye J, Horwitz B, Rapoport S. Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology 1990;40(6):872-883.
11. Jobst KA, Jaskowski A, McDonald B, Wald N. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992;340(8829):1179-1183.
12. de Leon MJ, Golomb J, George AE, Convit A, Tarshish CM, McRae T. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. Am J Neuroradiol 1993;14(4):897-906.
13. Willmer J, et al. The usefulness of CT scanning in diagnosing dementia of the Alzheimer type. Can J Neurol Sci 1993;20(3):210-216.
14. de Leon MJ, Convit A, George AE, et al. In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease. Ann N Y Acad Sci 1996;777:1-13.
15. Gado M, Hughes CP, Danziger WL, Chi D, Jost G, Berg L. Volumetric measurements of the cerebrospinal fluid spaces in demented subject and controls. Radiology 1981;144:535538.
16. Sandor T, Albert M, Stafford J, Harpley S. Use of computerized CT analysis to discriminate between Alzheimer patients and normal control subjects. Am J NeuroradioL 1988;9(6):1181-1187
17. Burns A, Jacoby R, Philpot M. Computerised tomography in Alzheimer's disease. Methods of scan analysis, comparison with normal controls, and clinical/radiological associations. Br J Psychiatry 1991;159:609-614.
18. Massman PJ, et al. The relationship between cortical atrophy and ventricular volume. Int J Neurosci 1986;30(1-2):8799.
19. Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early durin progression of Alzheimer's disease. Neurology 2001;56:127-129.
20. Bird JM, Levy R, Jacoby RJ. Computed tomography in the elderly: changes over time in a normal population. Br J Psychiatry 1986;148:80-85.
21. Pfefferbaum A, Sullivan EV, Jernigan TL, et al. A quantitative analysis of CT and cognitive measures in normal aging and Alzheimer's disease. Psychiatry Res 1990;35(2):115-136.
22. Wippold FJ II, Gado M, Morris JC, Duchek J, Grant EA. Senile dementia and healthy aging: a longitudinal CT study. Radiology 1991;179(1):215-219.
23. Luxenberg JS, Haxby JV, Creasy H, Sundaram M, Rapoport SI. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration. Neurology 1987;37(7):11351140.
24. de Leon MJ, George AK, Reisberg B, et al. Alzheimer's disease: longitudinal CT studies of ventricular change. Am J Roentgenol 1989;152(6):1257-1262.
25. Burns A, Jacoby R, Levy R. Computed tomography in Alzheimer's disease: a longitudinal study. Biol Psychiatry 1991;29(4):383-390.
26. DeCarli C, Haxby JV, Gillette JA, Teichberg D, Rapoport SI, Shapiro MB. Longitudinal changes in lateral ventricular volume in patients with dementia of the Alzheimer type. Neurology 1992;42(10):2029-2036.
27. Shear PK, Sullivan EV, Mathalon DH, et al. Longitudinal volumetric computed tomographic analysis of regional brain changes in normal aging and Alzheimer's disease. Arch Neurol 1995;52(4):392-402.
28. Jack CR Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normal volumetric measurements for MR images in young adults. Radiology 1989;172:549-554.
29. Jack CR Jr, Petersen RC, O'Brien PC, Tangalous EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992;42:183-188.
30. Killiany RJ, Moss MB, Albert MAT, Sandor TJ, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 1993;50:949-954.
31. Kido DK, et al. Temporal lobe atrophy in patients with Alzheimer disease: a CT study. Am J Neuroradiol 1989;10(3):551-555.
32. Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997;48:12971304.
33. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45(3):358-368.
34. Perl DP. Neuropathology of Alzheimer's disease and related disorders. Neurol Clin 2000;18:847-864.
35. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
36. Simic G, Kostovic I, Winblad B, Bogdanovic N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurology 1997;379(4):482-494.
37. George AE, de Leon MJ, Stylopoulos LA, et al. CT diagnostic features of Alzheimer disease: importance of the choroidal/hippocampal fissure complex. Am J Neuroradiol 1990;11:101-107.
38. de Leon MJ, et al. Early marker for Alzheimer's disease: the atrophic hippocampal formation. Lancet 1989;2:672673.
39. Denihan A, Wilson G, Cunningham C, Coakley D, Lawlor BA. CT measurement of medial temporal lobe atrophy in Alzheimer's disease, vascular dementia, depression and paraphrenia. Int J Geriatr Psychiatry 2000;15(4):306-312.
40. Pasquier F, Bail L, Lebert F, Pruvo JP, Petit H. Determination of medial temporal lobe atrophy in early Alzheimer's disease with computed tomography. Lancet 1994;343 (8901):861-862.
41. Jack CR Jr, Petersen RC, Xu Y, et al. The rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998;51:993-999.
42. Lehericy S, Baulac M, Chiras J, et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. Am J Neuroradiol 1994;15:927937.
43. Honeycutt NA, Smith PD, Aylward E, et al. Mesial temporal lobe measurements on magnetic resonance imaging scans. Psychiatry Res 1998;83(2):85-94.
44. Horn R, et al. Atrophy of hippocampus in patients with Alzheimer's disease and other diseases with memory impairment. Dementia 1996;7(4):182-186.
45. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal aging: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-972.
46. Convit A, de Leon MJ, Golomb J, et al. Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatric Q 1993;64(4):371-387.
47. Laakso MP, et al. Volumes of hippocampus, amygdala and front lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions. J Neural Transm 1995;9:73-86.
48. Fox NC, Warrington EK, Freeborough PA, Kennedy AM, Stevens JM, Rossor MN. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996;119:2001-2007.
49. Csernansky JG, Wang L, Joshi S, et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology 2000;55:1636-1643.
50. Hogan RE, Mark KE, Wang L, Joshi S, Miller MI, Bucholz RD. Mesial temporal sclerosis and temporal lobe epilepsy: MR imaging deformation-based segmentation of the hippocampus in five patients. Radiology 2000;216(1):291-297.
51. Kuzniecky RI, Burgard S, Bilir E, et al., Qualitative MRI segmentation in mesial temporal sclerosis: clinical correlations. Epilepsia 1996;37:433-439.
52. Xu Y, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000;54:17601767.
53. Bobinski M, de Leon MJ, Convit A, et al. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet 1999;353:38-40.
54. Juottonen K, Laakso MP, Insausti R, et al. Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol Aging 1998;19(1)::15-22.
55. Insausti R, Juottonen K, Soininen H, et al. MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices. Am J Neuroradiol 1998;19:659-671.
56. Cuenod C-A, Denys A, Michot J-L. Amygdala atrophy in Alzheimer's disease. An in vivo magnetic resonance imaging study. Arch Neurol 1993;50:941-945.
57. Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994;343(8901):829-830.
58. Fisch B, Dale AM. Measuring the thickness of the human cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000;97:11050-11055.
59. Gadian D., ed. NMR and Its Application to Living Systems. 2nd ed. Oxford, UK: Oxford University Press; 1995.
60. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992;59:55-61.
61. Klunk WE, et al. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 1992;42(8):1578-1585.
62. Kwo-On-Yuen PF, Newmark RD, Budinger TF, Kaye JA, Ball MJ, Jagust WJ. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Res 1994;667(2):167-174.
63. Mohanakrishnan P, Fowler AH, Vonsattel JP. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res 1995;102(3):503-510.
64. Mohanakrishnan P, Fowler AH, Vonsattel JP, et al. Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum. J Gerontol Ser A Biol Sci Med Sci 1997;52(2):B111-B117.
65. Bilken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H MRS. Neurosci Biobehav Rev 1989;13:23-31.
66. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. Part II: metabolite concentrations. J Magn Reson 1993;102:9-19.
67. Provencher SW. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
68. Satlin A, et al. Brain proton magnetic resonance spectroscopy (sup 1 H-MRS) in Alzheimer's disease: Changes after treatment with xanomeline, an M sub 1 selective cholinergic agonist. Am J Psychiatry 1997;154:1459-1461.
69. Parnetti L, Tarducci R, Presciutti O, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997;97(1):94-4.
70. Heun R, Schlegel S, Graf-Morgenstern M, et al. Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int J Geriatr Psychiatry 1997;12(3):349-358.
71. Rose SE, de Zubicaray GI, Wang D, et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 1999;17(2):291-299.
72. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;56(5):592-598.
73. Kantarci K, Jack CR Jr, Xu Y, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000;55:210-217.
74. Jessen F, Block W, Träber F, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000;55(5):684-688.
75. Jessen F, Block W, Träber F, et al. Decrease of Nacetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001;57:930-932.
76. Schuff N, Amend D, Meyerhoff DJ, et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998;207(1):91-102.
77. Kreis R, Ross BD. Cerebral metabolic disturbances in patients with sub-acute and chronic diabetes mellitus by proton magnetic resonance spectroscopy. Radiology 1992;184:123-130.
78. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with 1H MRS. Radiology 1992;182:19-27.
79. Miller BL, Moats R, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology 1993;187(2):433-437.
80. Shiino A, Matsuda M, Morikawa S, Inubushi T, Akignchi I, Handa J. Proton magnetic resonance spectroscopy with dementia. Surg Neurol 1993;39(2):143-147.
81. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32(1):110-115.
82. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195(1):65-72.
83. Ernst T, Chang L, Melchor R, Mehringer M. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997;203(3):829-386.
84. Ross BD, Bluml SB, Cowan R, et al. In vivo MR spectroscopy of human dementia. Neuroimaging Clin North Am 1998;8(4):809-822.
85. Basser PJ, Pierpaoli C. A simplified method to measure the diffusion tensor from seven MR images. Magn Reson Med 1998;39(6):928-934.
86. Conturo TE, Lori NF, Cull TS, et al., Tracking neuronal fiber pathways in the living human brain. Proc Natl Acad Sci USA 1999;96(18):10422-10427.
87. Kantarci K, et al. Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 2001;219:101-107.
88. Bahn MM. A linear relationship exists among brain diffusion eigenvalues measured by diffusion tensor magnetic resonance imaging. J Magn Reson 1999;137(1):33-38.
89. Rose SE, et al. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with color coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 2000;69:528-530.
90. Bozzali M, Franceschi M, Falini A, et al. Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. Neurology 2001;57:1135-1137.
91. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:711-714.
92. Foster NL, Chase TN, Fedio P, et al. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 1983;33:961-965.
93. Friedland RP, Budinger TF, Ganz E, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with (18F)fluorodeoxyglucose. J Comput Assist Tomogr 1983;7:590-598.
94. Duara R, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887.
95. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-1928.
96. Grady CL, Haxby JV, Schapiro MB, et al. Subgroups in dementia of the Alzheimer type identified using positron emission tomography. J Neuropsychiatry Clin Neurosci 1990;2:373-384.
97. Haxby JV, et al. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab 1985;5:193-200.
98. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. J Am Med Assoc 2001;286:2120-2127.
99. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-1593.
100. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
101. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:60376042.
102. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using threedimensional stereotactic surface projections of fluorine-18 FDG PET. J Nucl Med 1995;36:1238-1248.
103. Tohgi H, Chiba K, Sasaki K, Hiroi S, Ishibashi Y. Cerebral perfusion patterns in vascular dementia of Binswanger type compared with senile dementia of Alzheimer type: a SPECT study. J Neurol 1991;238:365-370.
104. Motomura N, Seo T. Lateral hemispheric asymmetries in senile dementia of Alzheimer's type (SDAT) assessed by I-123 IMP SPECT imaging: a preliminary report. Int J Neurosci 1992;63:1-3.
105. van Gool WA, Walstra GJM, Teunisse S, van der Zant FM, Weinstein HC, van Royan EA. Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol 1995;242:401-405.
106. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDSADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1997;9(suppl 1):191-222.
107. Ryding E. SPECT measurements of brain function in dementia; a review. Acta Neurol Scand Suppl 1996;168:5458.
108. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;9:21-27.
109. Nordberg A, Lundqvist H, Hartvig P, et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 1997;8:78-84.
110. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699.
111. Graeber MB. Glial inflammation in neurogenerative diseases. Immunology 2001;101 (suppl 1):52.
112. Banati RB. Visualising microglial activation in vivo. Glia 2002;40:206-217.
113. Cagnin A, Brooks DJ, Kennedy AM, et al. In vivo measurement of activated microglia in dementia. Lancet 2001;358:461-467.
114. Cagnin A, et al. In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 2002;12:581-586.
115. Bacskai BJ, et al. Imaging amyloid-β deposits in vivo. J Cereb Blood Flow Metab 2002;22:1035-1041.
116. Kung MP, et al. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J Mol Neurosci 2002;19:710.
117. Okamura N, et al. New imaging probes for in vivo labeling of amyloid plaques and neurofibrillary tangles. Neurobiol Aging 2002;23(suppl 1):S352.
118. Sawada T. Imaging amyloid. Neurobiol Aging 2002;23(suppl 1):S563.
119. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
120. Engler H, et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging 2002;23(suppl 1):S429.
121. Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA 1992;89:5951-5955.
122. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A 1992;89:5675-5679.
123. Kuschinsky W. Regulation of cerebral blood flow. In: Imoonen C, Bandettini P, eds. Functional MRI. New York: Springer; 1999:15-23.
124. Villringer A. Physiological changes during brain activation. In: Imoonen C, Bandettini P, eds. Functional MRI. New York: Springer; 1999:3-13.
125. Boynton GM, Engel SA, Glover GH, Heeger DJ. Linear systems analysis of functional magnetic resonance imaging in human V1.J Neurosci 1996;16:4207-4221.
126. Heeger DJ, Ress D. What does fMRI tell us about neuronal activity? Nature Rev Neurosci 2002;3:142-151.
127. Logothetis NK, et al. Neurophysiological investigation on the basis of the fMRI signal. Nature Rev Neurosci 2001;412:150-157.
128. Davis TL, Kwong KK, Weisskoff RM, Rosen BR. Calibrated functional MRI: mapping the dynamics of oxidative metabolism. Proc Natl Acad Sci U S A 1998;95:18341839.
129. D'Esposito M, Zarahn E, Aguirre GK, Rypma B. The effect of normal aging on the coupling of neural activity to the BOLD hemodynamic response. Neuro Image 1999;10:6-14.
130. Buckner RL, Snyder AZ, Sanders AL, Raichle ME, Morris JC. Functional brain imaging of young, nondemented, and demented older adults. J Cogn Neurosci 2000;12:24-34.
131. Nagata K, Sato M, Satoh Y, et al. Hemodynamic aspects of Alzheimer's disease. Ann N Y Acad Sci 2002;977:391-402.
132. Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999;45:466-472.
133. Kato T, Knopman D, Liu H. Dissociation of regional activation in mild AD during visual encoding. Neurology 2000;57:812-816.
134. Petrella JR, Lustig C, Buchler LA, Jha AP, Doraiswamy PM. Prefrontal activation patterns in subjects at risk for Alzheimer disease. Am J Geriatr Psychiatry 2002;10:112-113.
135. Mentis M, Alexander GE, Krasuski J, et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry 1998;155:785-794.
136. Brookheimer SY, Strojwas M, Cohen M, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000;343:450-456.